Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively novel class of drug for treating type 2 diabetes mellitus (T2DM) that inhibits glucose reabsorption in the renal proximal tubule to promote glycosuria and reduce blood glucose levels. SGLT2i has been clinically indicated for treatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Dan, Chandler, Owain, Wee, Cleo, Ho, Chau, Affandi, Jacquita S., Yang, Daya, Liao, Xinxue, Chen, Wei, Li, Yanbing, Reid, Christopher, Xiao, Haipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419219/
https://www.ncbi.nlm.nih.gov/pubmed/34497814
http://dx.doi.org/10.3389/fmed.2021.712671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419219/
https://www.ncbi.nlm.nih.gov/pubmed/34497814
http://dx.doi.org/10.3389/fmed.2021.712671

Ejemplares similares